1
|
Kang YM, Kim YJ, Kim K. Significance of traditional herbal medicine for dyslipidemia. Am J Transl Res 2023; 15:5373-5388. [PMID: 37692941 PMCID: PMC10492084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 08/13/2023] [Indexed: 09/12/2023]
Abstract
Dyslipidemia is a multifactorial disorder that is a causative factor and risk factor for cardiovascular disease. The incidence of dyslipidemia is expected to increase because of the presence of comorbidities. Although several lipid-lowering drugs have been developed and approved, they are not completely effective and are associated with side effects. Traditional herbal medicine (THM) represents an alternative and complementary approach for managing dyslipidemia because of its low toxicity and beneficial effects, such as anti-inflammatory and antioxidant effects. This review focuses on our current understanding of the antidyslipidemic effect of THMs and discusses the associated regulatory mechanisms. The current findings indicate that THM may lead to the development of novel therapeutic regimens for dyslipidemia.
Collapse
Affiliation(s)
- Yun-Mi Kang
- Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM)Daegu 41062, Republic of Korea
| | - Yeon-Ji Kim
- Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM)Daegu 41062, Republic of Korea
| | - Kyungho Kim
- Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM)Daegu 41062, Republic of Korea
- Korean Convergence Medical Science Major, KIOM School, University of Science and Technology (UST)Daejeon 34054, Republic of Korea
| |
Collapse
|
2
|
Hong F, Xu P, Zhai Y. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. Int J Mol Sci 2018; 19:ijms19082189. [PMID: 30060458 PMCID: PMC6121873 DOI: 10.3390/ijms19082189] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Revised: 07/16/2018] [Accepted: 07/24/2018] [Indexed: 12/12/2022] Open
Abstract
Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer's disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
Collapse
Affiliation(s)
- Fan Hong
- Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
- Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
| | - Pengfei Xu
- Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
| | - Yonggong Zhai
- Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
- Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
| |
Collapse
|
3
|
Jiang B, Wang YJ, Wang H, Song L, Huang C, Zhu Q, Wu F, Zhang W. Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway. Br J Pharmacol 2016; 174:177-194. [PMID: 27861729 DOI: 10.1111/bph.13668] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 10/28/2016] [Accepted: 11/03/2016] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND AND PURPOSE Depression is a neuropsychiatric disorder accompanied by a decrease in the brain-derived neurotrophic factor (BDNF) signalling cascade in the hippocampus. Fenofibrate is a selective agonist of PPAR-α. In this study, we investigated the antidepressant-like effects of fenofibrate in C57BL/6J mice. EXPERIMENTAL APPROACH The antidepressant-like effects of fenofibrate were first identified in the forced swim test (FST) and tail suspension test (TST), and then assessed in the chronic social defeat stress (CSDS) model. The changes in the hippocampal BDNF signalling pathway and adult hippocampal neurogenesis after CSDS and fenofibrate treatment were further investigated. A PPAR-α inhibitor, cannabinoid system inhibitors and BDNF signalling inhibitors were also used to determine the antidepressant mechanisms of fenofibrate. KEY RESULTS Fenofibrate administration exhibited antidepressant-like effects in the FST and TST without affecting the locomotor activity of mice. Chronic fenofibrate treatment also prevented the depressive-like symptoms induced by CSDS. Moreover, fenofibrate restored the CSDS-induced decrease in the hippocampal BDNF signalling cascade and adult hippocampal neurogenesis. The antidepressant-like effects of fenofibrate could be blocked by a PPAR-α inhibitor and BDNF signalling inhibitors. CONCLUSIONS AND IMPLICATIONS Taken together, these results suggest that fenofibrate has antidepressant-like effects mediated through the promotion of the hippocampal BDNF signalling cascade.
Collapse
Affiliation(s)
- Bo Jiang
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| | - Ying-Jie Wang
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| | - Hao Wang
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| | - Lu Song
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| | - Chao Huang
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| | - Qing Zhu
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| | - Feng Wu
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| | - Wei Zhang
- Department of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.,Provincial key laboratory of Inflammation and Molecular Drug Target, Nantong, Jiangsu, China
| |
Collapse
|
4
|
Patel H, Rathod R, Dash RP, Nivsarkar M. SIMULTANEOUS QUANTIFICATION OF ROSUVASTATIN AND FENOFIBRIC ACID BY HPLC-UV IN RAT PLASMA AND ITS APPLICATION TO PHARMACOKINETIC STUDY. J LIQ CHROMATOGR R T 2014. [DOI: 10.1080/10826076.2013.807462] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Hitesh Patel
- a Department of Pharmaceutical Analysis , National Institute of Pharmaceutical Education and Research-Ahmedabad, Thaltej , Ahmedabad , Gujarat , India
| | - Rajeshwari Rathod
- b Department of Pharmaceutical Analysis , B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej , Ahmedabad , Gujarat , India
| | - Ranjeet Prasad Dash
- c Department of Pharmacology and Toxicology , B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej , Ahmedabad , Gujarat , India
| | - Manish Nivsarkar
- c Department of Pharmacology and Toxicology , B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej , Ahmedabad , Gujarat , India
| |
Collapse
|
5
|
Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. CLINICAL MEDICINE INSIGHTS-CARDIOLOGY 2012; 6:17-33. [PMID: 22442638 PMCID: PMC3303484 DOI: 10.4137/cmc.s4324] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers published in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Finally we address its place in clinical practice.
Collapse
Affiliation(s)
- Ahai Luvai
- Department of Clinical Biochemistry, Leeds General Infirmary, LS1 3EX
| | - Wycliffe Mbagaya
- Department of Clinical Biochemistry, Leeds General Infirmary, LS1 3EX
| | | | - Julian H. Barth
- Department of Clinical Biochemistry, Leeds General Infirmary, LS1 3EX
| |
Collapse
|